Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORIC-114 + amivantamab
- Development stage
- Unknown
- Lead developer
- ORIC Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
ORIC-114 + amivantamab is an investigational combination therapy being evaluated for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. ORIC-114 is a highly selective, brain penetrant, orally bioavailable, irreversible inhibitor designed to target both EGFR and HER2 with high potency and minimal off-target toxicity. Amivantamab (marketed as Rybrevant) is a fully human bispecific monoclonal antibody that targets both EGFR and MET receptors. The combination aims to address therapeutic resistance in NSCLC patients, particularly those with brain metastases or who have progressed on prior therapies. A Phase 1b trial sponsored by ORIC Pharmaceuticals in collaboration with Janssen Research & Development (a Johnson & Johnson company) will assess safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of this regimen[1][3][6][7].
- Brand names
- Rybrevant
- Other names
- none
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on ORIC-114 + amivantamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORIC-114 + amivantamab.